BRIDGING THE GAP BETWEEN MEDICAL DISCOVERIES AND IMPROVED HEALTH
THE TRI WAY

The Translational Research Institute (TRI) is where science, medicine and industry intersect. TRI provides innovative medical research, development, and translation.

This unique, award winning facility is home to a range of cutting edge science and technology developments. TRI is at the forefront of prevention, treatment and diagnosis of modern day health problems and diseases.

Supported by a grant from the Australian and Queensland Governments, and situated on Brisbane’s Princess Alexandra (PA) Hospital campus, TRI combines the research intellect and capability of the Queensland Government, Queensland University of Technology, The University of Queensland and Mater Research.

TRI leases one of its buildings to the biopharmaceutical manufacturer, Patheon Biologics, making it one of a few places in the world where new biopharmaceuticals and treatments can be discovered, produced, clinically tested and manufactured in the one location.

“TRI is a disruption to business as usual. We connect scientists with clinicians to solve healthcare problems. We are a catalyst for change. Our goal is to improve the percentage of medical innovations that are translated and made available worldwide. Our ultimate outcome - improved healthcare, jobs and manufacturing industries.”

CEO Professor Carolyn Mountford
OUR HISTORY

The translational success of founding CEO Professor Ian Frazer’s Gardasil vaccine for cervical cancer acted as the catalyst and inspiration for TRI to become a reality in 2013. Professor Frazer understood first-hand the challenges of progressing his research through a complicated system to arrive at a place where it would benefit society.

As a result we are Australia’s first translational institute conceived and constructed to interface with patients, clinicians, scientists, mathematicians, health economists and engineers.

“We have to get better at choosing the discoveries and understanding how to best test them clinically to justify the investment. To achieve this we need scientists and investors who understand the clinical and commercial issues and how to initiate the process correctly.”

Professor Ian Frazer AC
Founding TRI CEO
WHAT IS TRANSLATIONAL RESEARCH?

Translational Research aims to convert scientific innovations into health gains. It involves a multidisciplinary approach, early involvement with a commercial partner and a focus on positive outcomes for patients, the community and world health.

The work at TRI is driven by the needs of patients, a question formed by a clinician and a solution sought by a scientist. While traditionally, clinicians and researchers worked separately, this improved method ensures patient needs are our priority and that teams share knowledge which multiplies with every collaboration.

These teams also create a feedback loop which is essential to the translational pathway. With the clinician and scientist working side by side with the patient, results can be obvious immediately.
THE TRI TRANSLATIONAL PATHWAY

The TRI translational pathway is both a communication and resource tool, used to explain, standardise and simplify a complex process across a wide variety of scientific and clinical research.

The model enables TRI to see where research projects are at and to identify and overcome roadblocks that may be preventing research from progressing to its next stage.

Each step from T1 to T5 involves achieving significant progress towards answering a clinical question and a positive patient outcome.

Examples of projects at each stage of the TRI Translational Pathway can be found at www.tri.edu.au/projects
OUR RESEARCH

TRI research is driven by identifying clinical problems and solving them with innovation and commercial partnerships.

Over 900 clinicians and researchers from TRI's four partner organisations undertake medical research, development and translation into a range of areas including: cancer, inflammation and infection; obesity and diabetes; kidney and liver diseases; brain and bone trauma; and autoimmune diseases.

The research aims to:
• Improve early detection, diagnosis, treatment and recovery
• Reduce the risk of disease spreading
• Relieve symptoms and better manage chronic diseases and trauma
• Prevent disease and provide protection against infection.
WEALTH OF KNOWLEDGE

TRI works to attract and nurture the best and brightest researchers and clinicians.

The collective expertise of TRI is fundamental to Australia’s investment in building a knowledge-based economy.

TRI is also an educational facility in the fields of medicine and science, housing The University of Queensland School of Medicine and School of Nursing and Midwifery and Queensland University of Technology student’s studying in radiography, biomedical science, nursing, paramedic science, public health and trauma.
WORLD CLASS FACILITIES

The seven storey, 35,500 square meter TRI building incorporates four floors of state of the art laboratories.

World-class, emerging technologies are available to researchers onsite through shared speciality facilities including:
- Clinical imaging
- Preclinical imaging
- Microscopy
- Proteomics and mass spectrometry
- Flow cytometry
- Histology
- Biological research facility

Two Clinical Research Facilities operate at the Princess Alexandra Hospital and Lady Cilento Children's Hospital to provide a controlled and safe environment to conduct patient research.
SUPPORT TRI

Donate
With support from you, researchers at TRI can continue to fight disease. You can be part of the bigger picture by making a tax-deductible donation to the TRI Foundation.

Visit www.tri.edu.au/donations

Get Involved
Follow or like TRI on social media including Facebook, Twitter, LinkedIn, and watch our videos on YouTube

Find out more about medical research by attending a community event at TRI.

Sign up to our newsletter at www.tri.edu.au

Corporate and Commercial Partnerships
Explore the opportunities to build new partnerships which involve your business in the creation of life-saving therapies to treat cancers, infectious diseases or other life-threatening or life-limiting conditions. TRI collaborates with commercial enterprises, in house and externally, as well as governments to be a world-test site for emerging technologies.

Find out more www.tri.edu.au
TRI’S CAPACITY TO TRANSLATE MEDICAL TREATMENTS INTO IMPROVED HEALTH CARE HAS BEEN MADE POSSIBLE THROUGH FUNDING FROM THE AUSTRALIAN AND QUEENSLAND GOVERNMENTS, THE QUEENSLAND UNIVERSITY OF TECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AND ATLANTIC PHILANTHROPIES.